Related Experiment Videos
Timegadine: long-term open study in rheumatoid arthritis
Clinical Rheumatology
|December 1, 1983
Summary
Timegadine, a novel antirheumatic agent, showed significant improvements in rheumatoid arthritis symptoms and laboratory markers within 6 weeks. Further benefits were observed during the 24-week trial, indicating its potential as a remissive drug.
Area of Science:
- Rheumatology
- Pharmacology
- Clinical Medicine
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and progressive damage.
- Existing treatments for RA aim to reduce inflammation, alleviate pain, and slow disease progression.
- Novel therapeutic agents are continuously sought to improve patient outcomes and disease management.
Purpose of the Study:
- To evaluate the efficacy and tolerability of Timegadine, a new antirheumatic agent, in patients with active rheumatoid arthritis.
- To assess the impact of Timegadine on both subjective and objective clinical parameters of RA.
- To investigate the effects of Timegadine on laboratory markers of disease activity, including erythrocyte sedimentation rate (ESR) and rheumatoid factor (RF) titre.
Main Methods:
- An open-label trial involving 31 patients with active rheumatoid arthritis.
- Patients received Timegadine at a dose of 250 mg twice daily for 24 weeks.
- Clinical parameters, laboratory markers (ESR, RF titre), and side effects were monitored throughout the study.
Main Results:
- Significant improvements in subjective and objective clinical parameters were observed from week 2 to week 6.
- Erythrocyte sedimentation rate (ESR) significantly decreased by week 6, with continued reduction during treatment.
- Humoral parameters of RA disease activity were significantly modified by the end of the 24-week treatment period.
- A reduction in rheumatoid factor titre by at least two dilutions was noted in 65% of seropositive patients.
- Five patients (16%) discontinued treatment due to side effects.
Conclusions:
- Timegadine demonstrated significant efficacy in improving clinical and laboratory parameters of rheumatoid arthritis.
- The drug was generally well-tolerated, although some patients experienced side effects.
- The observed improvements suggest Timegadine holds potential as a remissive agent for rheumatoid arthritis, warranting further investigation.